Syndax banks an $80M crossover round for PhIII cancer drug

John Carroll

Two months after signing up AstraZeneca R&D leader Briggs Morrison as its new CEO, Waltham, MA-based has raised $ 80 million from a syndicate that includes a group of high-profile investors.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS